GlaxoSmithKline (GSK) is one of the largest players in the global pharmaceutical industry, vaccinations and consumer healthcare, and employs 97,000 people throughout the world. GSK produces a large portfolio of products for illnesses such as asthma, cancer, viruses, infections, mental health, diabetes and stomach/intestinal disorders.

The Task
GSK was looking for a proven benchmark methodology to support the maintenance aspect of its Operational Excellence Program. Mainnovation provided its myVDMXL.com online benchmark platform, making GSK UK one of the first foreign companies to embrace VDMXL.

The Approach
GSK has integrated the VDMXL value driver methodology into its method of work as a means of reviewing the performance of its maintenance organizations each year. All GSK plants are audited annually by internal VDMXL champions. The value potential of each plant is calculated and the organization is benchmarked in terms of maturity and performance. Mainnovation trained internal auditors who make use of myVDMXL.com. The improvement potential identified using VDMXL has since exceeded € 10 million per year. To exploit this improvement potential, various VDMXL best practices were integrated into the existing global maintenance management program. These are then used to raise specific competences to a higher level of maturity.

Mainnovation’s Added Value
The Operational Excellence Program is in full swing and has by now resulted in a value potential of over € 10 million in annual cost savings (Cost Control). This is further enhanced by a great deal of value in GSK plants that focus on increasing their uptime (Asset Utilization).

The improvement potential identified using VDMXL has since exceeded € 10 million per year.

 

gsk2-foto

more cases

  • Elaboration of a Maintenance & Asset Management roadmap for the coming 2 years

  • Each plant is compared in terms of the qualitative and quantitative benchmark data.

  • Improvement potential over €10 million per year